In vitro and in vivo toxicity and histopathological evaluation of Gd(III)anionic Linear globular dendrimer second-generation G۲-C۵۹۵ nanoprobe

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 340

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

این مقاله در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_NAMJ-7-4_004

تاریخ نمایه سازی: 6 اردیبهشت 1400

چکیده مقاله:

Objective(s): Toxico-histopathological studies are used to assess the toxic impacts of nanoparticles in organism exposure. The present study aimed to evaluate the prospective nano-cytotoxicity impacts of Gd(III)-anionic linear globular dendrimer second-generation G۲-C۵۹۵ (Gd[III] dendrimer G۲-C۵۹۵) contrast nanoprobe in terms of the exposure of many nude mice organs and organisms. In addition, we assessed the potential of the Gd(III)-dendrimer G۲-C۵۹۵ nanoprobe as a novel magnetic resonance imaging (MRI) nano-contrast agent for the human breast cancer cell line (MCF-۷) and human embryonic kidney cell line (HEK-۲۹۳).Materials and Methods: Gadolinium (Gd[III]) was loaded with dendrimer G۲ and conjugated with the C۵۹۵ monoclonal antibody to generate the Gd(III)-dendrimer G۲-C۵۹۵ to determine the impact on MUC۱ beneficial cancer tumors. The cytotoxic effects of the Gd(III)-dendrimer G۲-C۵۹۵ nanoprobe on the HEK-۲۹۳ cells were also investigated in-vitro and in-vivo. In addition, the Gd(III)-dendrimer G۲-C۵۹۵ nanoprobe was used on nude mice bearing the MCF-۷ tumors to explore its specific activity against the in-vivo model of cancer.Results: The Gd(III)-dendrimer G۲-C۵۹۵ contrast nanoprobes affected the cytotoxicity of MCF-۷, and no in-vivo toxicity was induced in the HEK-۲۹۳ cells, kidneys, heart, lungs, brain, liver tissues, and other organs.Conclusion: According to the results, the Gd(III)-dendrimer G۲ and Gd(III)-dendrimer G۲-C۵۹۵ induced no toxicity in the HEK-۲۹۳ cells and heart, liver, and brain tissues of mice. In addition, the Gd(III)-dendrimer G۲-C۵۹۵ showed specific anti-action against the in-vivo tumor model. Therefore, the Gd(III)-dendrimer G۲-C۵۹۵ nanoprobe is highly recommended as a novel and effective MR contrast agent and antitumor carrier agent. Furthermore, the Gd(III)-dendrimer G۲-C۵۹۵ nano-sized probes demonstrated excellent biocompatibility and safety with no impact on normal organ functioning.

کلیدواژه ها:

Gd(III)-Dendrimer G۲-C۵۹۵ Nanoprobe ، Human Embryonic Kidney Cells (HEK-۲۹۳) ، human breast cancer cell line (MCF-۷) ، Nanoparticle Toxicity

نویسندگان

Mehdi Mirzaei

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Mohammad Esmaeil Akbari

Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Mohammad Ali Mohagheghi

Cancer Institute Research Center, Tehran University of Medical Sciences, Tehran, Iran

Seyed Mohammad Tavangar

Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Bita Mehravi

Department of Medical Nanotechnology, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran

Mehdi Shafiee Ardestani

Department of Radiopharmacy, School of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • 1.Yang Y, Qin Z, Zeng W, Yang T, Cao Y, ...
  • 2.Vandhana S, Nithya M, Deepak A. Review on nano toxic ...
  • 3.Hubbs AF, Sargent LM, Porter DW, Sager TM, Chen BT, ...
  • 4.Jain A, Dubey S, Kaushik A, Tyagi AK. Dendrimer: a ...
  • 5.Priya P, Sivabalan.Mand Jeyapragash R. Dendrimer: A Novel Polymer. Ijrpc. ...
  • 6.Wu L, Ficker M, Christensen JB, Trohopoulos PN, Moghimi SM. ...
  • 7.Noriega-Luna B, Godínez LA, Rodríguez FJ, Rodríguez A, Zaldívar-Lelo de ...
  • 8.Ye M, Qian Y, Tang J, Hu H, Sui M, ...
  • 9.Ornelas C, Pennell R, Liebes LF, Weck M. Construction of ...
  • 10.Majoros IJ, Williams CR, Baker JR Jr. Current dendrimer application ...
  • 11.Sherje AP, Jadhav M, Dravyakar BR, Kadam D. Dendrimers: A ...
  • 12.Chauhan AS. Dendrimers for Drug Delivery. Molecules. 2018; 23(4): 938. ...
  • 13.Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for ...
  • 14.Paleos CM, Tsiourvas D, Sideratou Z, Tziveleka LA. Drug delivery ...
  • 15.Gupta U, Dwivedi SK, Bid HK, Konwar R, Jain NK. ...
  • 16.Singh J, Jain K, Mehra NK, Jain NK. Dendrimers in ...
  • 17.Zheng Qiao, Xiangyang Shi. Dendrimer-based molecular imaging contrast agents. Prog ...
  • 18.Zhang S, Zheng Y, Fu DY, Li W, Wu Y, ...
  • 19.Mirzaei M, Mehravi B, Ardestani MS, Ziaee SA, Pourghasem P. ...
  • 20.Mullen DG, Fang M, Desai A, Baker JR, Orr BG, ...
  • 21.Klemm PJ, Floyd WC, Smiles DE, Frà chet JMJ, Raymond ...
  • 22.Longmire MR, Ogawa M, Choyke PL, Kobayashi H. Dendrimers as ...
  • 23.Rolland O, Turrin CT, Caminadeab AM, Majoral JP. Dendrimers and ...
  • 24.Jing X, Liang H, Hao C, Yang X, Cui X. ...
  • 25.Stergiou N, Nagel J, Pektor S, Heimes AS, Jäkel J, ...
  • 26.Lacunza E, Baudis M, Colussi AG, Segal-Eiras A, Croce MV, ...
  • 27.Mirzaei M, Esmaeil Akbari M, Mohagheghi MA, Ziaee SAM, Mohseni ...
  • 28.Mirzaei M, Mohseni M, Iranpour Anaraki N, Mohammadi E, Safari ...
  • 29.Shahbazi-Gahrouei D, Moradi Khaniabadi P, Moradi Khaniabadi B, Shahbazi-Gahrouei S. ...
  • 30.Ko YJ, Kim WJ, Kim K, Kwon IC. Advances in ...
  • 31.Rajamanickam K. Multimodal Molecular Imaging Strategies using Functionalized Nano Probes. ...
  • 32.Clough TJ, Jiang L, Wong KL, Long NJ. Ligand design ...
  • 33.Jeong Y, Hwang HS, Na K. Theranostics and contrast agents ...
  • 34.Carvalho A, Gonçalves MC, Corvo ML, Martins MBF. Development of ...
  • 35.Mirzaei M, Mohagheghi M, Shahbazi-Gahrouei D, Khatami A. Gd3+-Anionic Linear ...
  • 36.Mirzaei M, Shahbazi-Gahrouei D, Mohagheghi M. Synthesis and development of ...
  • 37.Lanone S, Boczkowski J. Biomedical applications and potential health risks ...
  • 38.Soto K, Garza KM, Murr LE. Cytotoxic effects of aggregated ...
  • 39.Elsaesser A, Howard CV. Toxicology of nanoparticles. Adv Drug Deliv ...
  • 40.Weyermann J, Lochmann D, Zimmer A. A practical note on ...
  • 41.Wörle-Knirsch JM, Pulskamp K, Krug HF. Oops they did it ...
  • 42.Mirzaei M, Mohagheghi M, Shahbazi-Gahrouei D, Khatami A. Novel Nanosized ...
  • نمایش کامل مراجع